Citigroup’s BioMarin Pharmaceuticals BMRN Stock Holding History

Citigroup’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.69M	Hold	30,000	–	–	﹤0.01%	2773
2025 Q4	$1.78M	Buy	30,000 +29,700	+9,900%	+$1.62M	﹤0.01%	2730
2025 Q3	$16.2K	Hold	300	–	–	﹤0.01%	4879
2025 Q2	$16.5K	Sell	300 -30,000	-99%	-$1.77M	﹤0.01%	5119
2025 Q1	$2.14M	Sell	30,300 -24,100	-44%	-$1.62M	﹤0.01%	2640
2024 Q4	$3.58M	Buy	54,400 +27,100	+99%	+$1.82M	﹤0.01%	2297
2024 Q3	$1.92M	Sell	27,300 -2,700	-9%	-$226K	﹤0.01%	2701
2024 Q2	$2.47M	Buy	+30,000	New	+$2.5M	﹤0.01%	2170
2023 Q4	–	Sell	-32,500	Closed	-$2.88M	–	5705
2023 Q3	$2.88M	Sell	32,500 -31,700	-49%	-$2.82M	﹤0.01%	1749
2023 Q2	$5.56M	Sell	64,200 -70,800	-52%	-$6.66M	﹤0.01%	1432
2023 Q1	$13.1M	Buy	135,000 +51,700	+62%	+$5.36M	0.01%	1020
2022 Q4	$8.62M	Buy	83,300 +48,300	+138%	+$4.53M	0.01%	1209
2022 Q3	$2.97M	Buy	+35,000	New	+$3.12M	﹤0.01%	1871
2022 Q2	–	Sell	-34,800	Closed	-$2.68M	–	6247
2022 Q1	$2.68M	Sell	34,800 -200,200	-85%	-$16.8M	﹤0.01%	2114
2021 Q4	$20.8M	Buy	+235,000	New	+$19.4M	0.01%	991
2021 Q1	–	Sell	-62,100	Closed	-$5.45M	–	6313
2020 Q4	$5.45M	Sell	62,100 -10,800	-15%	-$856K	﹤0.01%	2016
2020 Q3	$5.55M	Buy	72,900 +55,000	+307%	+$5.56M	﹤0.01%	1820
2020 Q2	$2.21M	Sell	17,900 -3,600	-17%	-$358K	﹤0.01%	2703
2020 Q1	$1.82M	Sell	21,500 -12,600	-37%	-$1.09M	﹤0.01%	2567
2019 Q4	$2.88M	Sell	34,100 -30,300	-47%	-$2.29M	﹤0.01%	2589
2019 Q3	$4.34M	Sell	64,400 -17,200	-21%	-$1.32M	﹤0.01%	2069
2019 Q2	$6.99M	Buy	81,600 +49,100	+151%	+$4.2M	0.01%	1681
2019 Q1	$2.89M	Sell	32,500 -5,700	-15%	-$528K	﹤0.01%	2265
2018 Q4	$3.25M	Buy	38,200 +1,900	+5%	+$181K	﹤0.01%	2225
2018 Q3	$3.52M	Buy	36,300 +22,000	+154%	+$2.2M	﹤0.01%	2191
2018 Q2	$1.35M	Sell	14,300 -3,600	-20%	-$315K	﹤0.01%	3056
2018 Q1	$1.45M	Sell	17,900 -11,500	-39%	-$987K	﹤0.01%	2899
2017 Q4	$2.62M	Buy	29,400 +2,600	+10%	+$226K	﹤0.01%	2415
2017 Q3	$2.5M	Sell	26,800 -10,200	-28%	-$901K	﹤0.01%	2420
2017 Q2	$3.36M	Sell	37,000 -67,400	-65%	-$6.13M	﹤0.01%	2066
2017 Q1	$9.16M	Buy	104,400 +37,100	+55%	+$3.3M	0.01%	1194
2016 Q4	$5.58M	Buy	67,300 +28,200	+72%	+$2.43M	0.01%	1719
2016 Q3	$3.62M	Sell	39,100 -11,500	-23%	-$1.08M	﹤0.01%	1971
2016 Q2	$3.94M	Buy	50,600 +38,000	+302%	+$3.23M	﹤0.01%	1788
2016 Q1	$1.04M	Sell	12,600 -2,400	-16%	-$195K	﹤0.01%	3291
2015 Q4	$1.57M	Sell	15,000 -110,500	-88%	-$11.5M	﹤0.01%	2675
2015 Q3	$13.2M	Buy	125,500 +11,300	+10%	+$1.51M	0.01%	952
2015 Q2	$15.6M	Buy	114,200 +110,500	+2,986%	+$13.7M	0.01%	931
2015 Q1	$461K	Buy	+3,700	New	+$392K	﹤0.01%	3816
2013 Q4	–	Sell	-107,300	Closed	-$7.75M	–	6981
2013 Q3	$7.75M	Buy	107,300 +70,200	+189%	+$4.67M	0.01%	1391
2013 Q2	$2.07M	Buy	+37,100	New	+$2.31M	﹤0.01%	2350

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's BMRN Position: Q1 2026 in Review

Citigroup increased its BioMarin Pharmaceuticals (BMRN) stake by 124% in Q1 2026, buying an estimated $12.7M and bringing the position to 393,895 shares worth $22.3M. The position accounts for 0.01% of the portfolio, ranked #1002.

Citigroup first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $32.7M in Q2 2020. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Citigroup held 393,895 shares of BioMarin Pharmaceuticals worth $22.3M as of Q1 2026.
Citigroup bought 217,669 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $12.7M.
BioMarin Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q1 2026, its #1002 holding.
Citigroup first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Citigroup's BioMarin Pharmaceuticals position peaked at $32.7M in Q2 2020.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.